Soleno Therapeutics, Inc. (SLNO) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Arbutus Biopharma Corp.

Arcutis Biotherapeutics, Inc.

Soleno Therapeutics, Inc.

Coherus BioSciences, Inc.

MacroGenics, Inc.

Nurix Therapeutics, Inc.

EyePoint Pharmaceuticals, Inc.

Erasca, Inc.

KalVista Pharmaceuticals, Inc.

Oric Pharmaceuticals, Inc.

Cullinan Therapeutics, Inc.

Why is Soleno Therapeutics, Inc. ?

With a growth in Net Sales of INF%, the company declared Very Positive results in Mar 26

The company has declared positive results for the last 4 consecutive quarters
OPERATING CASH FLOW(Y) Highest at USD 105.52 MM
NET SALES(HY) Higher at USD 186.33 MM
ROCE(HY) Highest at 26.27%

With ROE of 5.78%, it has a very attractive valuation with a 3.45 Price to Book Value

Over the past year, while the stock has generated a return of -29.86%, its profits have risen by 115.1% ; the PEG ratio of the company is 0.5

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Soleno Therapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Soleno Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Soleno Therapeutics, Inc.

-29.86%

0.16

77.98%

S&P 500

25.22%

1.78

12.93%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

186.02%

EBIT Growth (5y)

19.80%

EBIT to Interest (avg)

-54.29

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.03

Sales to Capital Employed (avg)

0.22

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.45

EV to EBIT

86.72

EV to EBITDA

76.41

EV to Capital Employed

6.64

EV to Sales

6.81

PEG Ratio

0.53

Dividend Yield

ROCE (Latest)

7.66%

ROE (Latest)

5.78%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

26What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 105.52 MM

NET SALES(HY)

Higher at USD 186.33 MM

ROCE(HY)

Highest at 26.27%

PRE-TAX PROFIT(Q)

At USD 35.4 MM has Grown at 186.74%

NET PROFIT(Q)

At USD 31.81 MM has Grown at 177.96%

RAW MATERIAL COST(Y)

Fallen by -9,873% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 12.09 times

-8What is not working for the Company

INTEREST(HY)

At USD 2.64 MM has Grown at 65.89%

DEBT-EQUITY RATIO (HY)

Highest at -40.61 %

Here's what is working for Soleno Therapeutics, Inc.

Pre-Tax Profit

At USD 35.4 MM has Grown at 186.74%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

At USD 31.81 MM has Grown at 177.96%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Net Sales

Higher at USD 186.33 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed sales of the previous twelve months

Net Sales (USD MM)

Operating Cash Flow

Highest at USD 105.52 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Debtors Turnover Ratio

Highest at 12.09 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -9,873% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Soleno Therapeutics, Inc.

Interest

At USD 2.64 MM has Grown at 65.89%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Debt-Equity Ratio

Highest at -40.61 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio